17.10.2024 14:13:08
|
Anavex Reports Promising EEG Biomarker Results From Phase 2 Study Of ANAVEX 3-71 For Schizophrenia
(RTTNews) - Anavex Life Sciences Corp. (AVXL) announced promising preliminary electroencephalography or EEG biomarker results from Part A of its ongoing placebo-controlled Phase 2 clinical study of ANAVEX 3-71 for the treatment of schizophrenia.
Part A of the Phase 2 study ANAVEX 3-71-SZ-001, was a multiple ascending dose study in 16 participants treated with either oral placebo, oral ANAVEX3-71 90 mg daily, or oral ANAVEX3-71 180 mg daily for 10 days.
According to the company, preliminary results demonstrated a dose-dependent effect of ANAVEX 3-71 on two key EEG biomarkers in patients with schizophrenia. Treatment with ANAVEX3-71 compared to placebo resulted in improvements in 40 Hz Auditory Steady-State Response (ASSR) Inter Trial Coherence (ITC) and Resting State Alpha Power, both of which were increased. The effects were most pronounced in the higher dose group demonstrating a dose-dependent pharmacodynamic effect.
Anavex noted that the results provide evidence of central nervous system (CNS) target engagement and potential therapeutic effects of ANAVEX3-71 in schizophrenia.
The company said that ANAVEX3-71 was well tolerated, with no serious adverse events reported.
The currently ongoing Part B of the placebo-controlled Phase 2 study, which includes more participants and a longer treatment duration, will provide more comprehensive data on the efficacy and safety of ANAVEX3-71 in schizophrenia, the company said.
Anavex expects data from Part B of the placebo-controlled Phase 2 study in the first half of 2025.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Anavex Life Sciences Corpmehr Nachrichten
Keine Nachrichten verfügbar. |
Analysen zu Anavex Life Sciences Corpmehr Analysen
Aktien in diesem Artikel
Anavex Life Sciences Corp | 7,42 | -1,77% |
|